1. Therapy for Pulmonary Arterial Hypertension in Adults
James R. Klinger, MD, FCCP, C. Gregory Elliott, MD, FCCP, Deborah J. Levine, MD, FCCP, Eduardo Bossone, MD, PhD, FCCP, Laura Duvall, PharmD, BCPS, Karen Fagan, MD, Julie Frantsve-Hawley, PhD, Steven M. Kawut, MD, John J. Ryan, MD, Erika B. Rosenzweig, MD, Nneka Sederstrom, PhD, FCCP, Virginia D. Steen, MD, David B. Badesch, MD, FCCP 
CHEST 
Volume 155, Issue 3, Pages (March 2019)
DOI: /j.chest
Copyright © 2019 American College of Chest Physicians Terms and Conditions

2. Figure 1
Guideline algorithm for pharmacologic therapy for PAH in adults. Where multiple drug options are provided, there is no comparative effectiveness data to suggest greater benefit of one therapy over the other. In these situations, other factors, such as patient preferences & values, cost, and insurance coverage, may guide decision-making. CCB = calcium channel blocker; 6MWD = 6-min walk distance; FC = functional class; PAH = pulmonary arterial hypertension; PH = pulmonary hypertension; RV = right ventricular; WHO = World Health Organization.
CHEST  , DOI: ( /j.chest )
Copyright © 2019 American College of Chest Physicians Terms and Conditions

3. Figure 1
Guideline algorithm for pharmacologic therapy for PAH in adults. Where multiple drug options are provided, there is no comparative effectiveness data to suggest greater benefit of one therapy over the other. In these situations, other factors, such as patient preferences & values, cost, and insurance coverage, may guide decision-making. CCB = calcium channel blocker; 6MWD = 6-min walk distance; FC = functional class; PAH = pulmonary arterial hypertension; PH = pulmonary hypertension; RV = right ventricular; WHO = World Health Organization.
CHEST  , DOI: ( /j.chest )
Copyright © 2019 American College of Chest Physicians Terms and Conditions

4. Figure 1
Guideline algorithm for pharmacologic therapy for PAH in adults. Where multiple drug options are provided, there is no comparative effectiveness data to suggest greater benefit of one therapy over the other. In these situations, other factors, such as patient preferences & values, cost, and insurance coverage, may guide decision-making. CCB = calcium channel blocker; 6MWD = 6-min walk distance; FC = functional class; PAH = pulmonary arterial hypertension; PH = pulmonary hypertension; RV = right ventricular; WHO = World Health Organization.
CHEST  , DOI: ( /j.chest )
Copyright © 2019 American College of Chest Physicians Terms and Conditions

5. Figure 2
Combination therapy algorithm. Where multiple drug options are provided, there is no comparative effectiveness data to suggest greater benefit of one therapy over the other. In these situations, other factors, such as patient preferences & values, cost, and insurance coverage, may guide decision-making. See Figure 1 for Boxes 1 and 2. See Figure 1 legend for expansion of abbreviations.
CHEST  , DOI: ( /j.chest )
Copyright © 2019 American College of Chest Physicians Terms and Conditions

6. Figure 3 General measures algorithm.
CHEST  , DOI: ( /j.chest )
Copyright © 2019 American College of Chest Physicians Terms and Conditions